Gano Kyle's Form 4 filing
Neurocrine Biosciences Inc (NBIX) · filed Sep 15, 2026
- Accession no.
- 0001567160-26-000009
- Filed
- Sep 15, 2026, 5:05 PM ET
- Trade date
- Sep 11, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gano KyleCIK 0001567160 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Common Stock | AGrant or awardAcquired | +6,275 | $0.00 | $0 | 157,266 | Direct | |
| Sep 11, 2026 | Common Stock | FTax withholdingDisposed | −3,386 | $156.22 | −$528,960.92 | 153,880 | Direct | |
| Sep 11, 2026 | Common Stock | AGrant or awardAcquired | +1,842 | $0.00 | $0 | 155,722 | Direct | |
| Sep 11, 2026 | Common Stock | FTax withholdingDisposed | −994 | $156.22 | −$155,282.68 | 154,728 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.